A phase II, multicenter, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid, CC-5013) in subjects with relapsed or refractory indolent non-Hodgkin's lymphoma
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2016
At a glance
- Drugs Lenalidomide (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 02 Jun 2009 Final results presented at ASCO 2009.
- 05 Dec 2006 Status change
- 22 Oct 2005 New trial record.